MHRA approves olaparib for high-risk, early-stage breast cancer 07 Sep 2022 The Institute of Cancer Research, London, celebrates the news that the precision medicine olaparib has been approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for patients with high-risk, early-stage breast cancer and inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
ICR welcomes MHRA approval of 'search and destroy' prostate cancer treatment 11 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer. Find out more Show/Hide